(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

We recently compiled a list of 11 Best Undervalued Stocks to Invest in Now. Lincoln National Corporation stands third on our ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

A new startup offering an AI-enabled threat-hunting platform is emerging from stealth today with backing from Bain Capital ...